抗ATRX抗体 (Anti-ATRX Antibody) | ヒト組織免疫染色用抗体
掲載日情報:2019/10/28 現在Webページ番号:9655
ATRXに対する抗体(Anti-ATRX Antibody)です。
高品質なTriple A Polyclonalsブランド抗体となります。
※本製品は研究用です。研究用以外には使用できません。
追加しました。
特長
- Atlas Antibodies社のポリクローナル抗体は「Atlas Antibodies Advanced Polyclonals」(Triple A Polyclonals)と称され、Atlas Antibodies社企業秘密のソフトウェアにより対象抗原タンパク質に対する最も適した、慎重にデザインされた抗体です。
- アフィニティーリガンドとしてリコンビナント抗原を用いた、Atlas Antibodies社独自の抗原精製過程により、特異性・信頼性・多様性が保持されています。
- 対応するリコンビナント抗原の取り扱いもあり(PrEST抗原)、ウエスタンブロット用のポジティブコントロール、および免疫組織染色での抗体ブロッキングに有用です。
- すべての抗体はHuman Protein Atlas (HPA) プロジェクトにて、様々な正常組織、腫瘍組織で検証されています。
- それぞれの抗体に対して700点以上の免疫組織染色、免疫蛍光染色、ウエスタンブロッティング像が公開されています。

Triple A Polyclonalsとは?
追加しました。
価格
[在庫・価格 :2025年04月27日 00時00分現在]
詳細 | 商品名 |
|
文献数 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anti-ATRX, Rabbit-Poly |
|
8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
[在庫・価格 :2025年04月27日 00時00分現在]
Anti-ATRX, Rabbit-Poly
文献数: 8
- 商品コード:HPA001906
- メーカー:AAB
- 包装:100μl
- 価格:¥112,000
- 在庫:1個
- 納期:2週間程度 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等:
説明文 | バリデーション情報:GENETIC, ORTHOGONAL, STANDARD 別名:JMS,RAD54,XH2,XNP Genbank No: 546 Protein Accession No: P46100 |
||||||
---|---|---|---|---|---|---|---|
別包装品 | 別包装品あり | ||||||
法規制等 | |||||||
保存条件 | -20℃ | 法規備考 | |||||
抗原種 | Human | 免疫動物 | Rabbit | ||||
交差性 | Human | 適用 | IC,IHC,Western Blot | ||||
標識 | Unlabeled | 性状 | Antigen Affinity Purified | ||||
吸収処理 | クラス | IgG | |||||
クロナリティ | Polyclonal | フォーマット | |||||
掲載カタログ |
|
||||||
製品記事 | Atlas Antibodies社文献使用抗体 |
||||||
関連記事 |
追加しました。
製品情報
免疫組織染色(IHC) ![]() | Staining of human liver shows no positivity in hepatocytes as expected. 推奨プロトコル(Recommended conditions) |
ウエスタンブロッティング(WB) ![]() | Western blot analysis in human cell line A-549. 推奨プロトコル(Recommended conditions) |
Comparison among conventional and advanced MRI, 18F-FDG PET/CT, phenotype and genotype in glioblastoma
Source
Oncotarget
Valentini MC, Mellai M, Annovazzi L, Melcarne A, Denysenko T, Cassoni P, Casalone C, Maurella C, Grifoni S, Fania P, Cistaro A, Schiffer D.
Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss
Source
Sci Rep
Li X, Wei J, Liu Y, Li P, Fan L, Wang Y, Li M, Zhao D, Yu Z, Ye J, Guo Y, Yan Q, Guo S, Wang Z.
Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach
Source
J Pathol Transl Med
Kim SI, Lee Y, Won JK, Park CK, Choi SH, Park SH.
The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas
Source
Acta Neuropathol Commun
Lee Y, Koh J, Kim SI, Won JK, Park CK, Choi SH, Park SH.
Expression and prognostic value of JAM-A in gliomas
Source
J Neurooncol
Rosager AM, Sørensen MD, Dahlrot RH, Boldt HB, Hansen S, Lathia JD, Kristensen BW.
IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas
Source
Clin Sarcoma Res
Cleven AH, Suijker J, Agrogiannis G, Briaire-de Bruijn IH, Frizzell N, Hoekstra AS, Wijers-Koster PM, Cleton-Jansen AM, Bovée JV.
PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma
Source
Oncotarget
Murnyák B, Kouhsari MC, Hershkovitch R, Kálmán B, Marko-Varga G, Klekner Á, Hortobágyi T.
DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors
Source
Oncotarget
Park JK, Paik WH, Lee K, Ryu JK, Lee SH, Kim YT.
Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome
Source
Oncotarget
Kiviniemi A, Gardberg M, Kivinen K, Posti JP, Vuorinen V, Sipilä J, Rahi M, Sankinen M, Minn H.
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Source
Oncotarget
Mohamed A, Romano D, Saveanu A, Roche C, Albertelli M, Barbieri F, Brue T, Niccoli P, Delpero JR, Garcia S, Ferone D, Florio T, Moutardier V, Poizat F, Barlier A, Gerard C.
Alternative lengthening of telomeres in primary pancreatic neuroendocrine neoplasms is associated with aggressive clinical behavior and poor survival
Source
Clin Cancer Res
Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, Kim MJ, Hwang DW, Meeker AK, Yu E, Kim SC, Hruban RH, Heaphy CM, Hong SM.
Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition
Source
Front Oncol
Deeg KI, Chung I, Bauer C, Rippe K.
Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic
Source
Oncotarget
Li YX, Shi Z, Aibaidula A, Chen H, Tang Q, Li KK, Chung NY, Chan DT, Poon WS, Mao Y, Wu J, Zhou L, Chan AK, Ng HK.
TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes
Source
Sci Rep
Vinagre J, Nabais J, Pinheiro J, Batista R, Oliveira RC, Gonçalves AP, Pestana A, Reis M, Mesquita B, Pinto V, Lyra J, Cipriano MA, Ferreira MG, Lopes JM, Sobrinho-Simões M, Soares P.
IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation
Source
Sci Rep
Oktay Y, Ülgen E, Can Ö, Akyerli CB, Yüksel Ş, Erdemgil Y, Durası İM, Henegariu OI, Nanni EP, Selevsek N, Grossmann J, Erson-Omay EZ, Bai H, Gupta M, Lee W, Turcan Ş, Özpınar A, Huse JT, Sav MA, Flanagan A, Günel M, Sezerman OU, Yakıcıer MC, Pamir MN, Özduman K.
ATRX binds to atypical chromatin domains at the 3′ exons of zinc finger genes to preserve H3K9me3 enrichment
Source
Epigenetics
Valle-García D, Qadeer ZA, McHugh DS, Ghiraldini FG, Chowdhury AH, Hasson D, Dyer MA, Recillas-Targa F, Bernstein E.
Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12
Source
PLoS Genet
Mäkinen N, Aavikko M, Heikkinen T, Taipale M, Taipale J, Koivisto-Korander R, Bützow R, Vahteristo P.
TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast
Source
British Journal of Cancer
Masayuki Yoshida, Reiko Ogawa, Hiroshi Yoshida, Akiko Maeshima, Yae Kanai, Takayuki Kinoshita, Nobuyoshi Hiraoka, Shigeki Sekine.
Adult Diffuse Astrocytoma in the Medulla Oblongata: Molecular Biological Analyses Including H3F3A Mutation of Histone H3.3
Source
NMC Case Rep J
Uekawa K, Nakamura H, Shinojima N, Takezaki T, Yano S, Kuratsu JI.
Molecular–genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort
Source
Oncotarget
Hayashi S, Sasaki H, Kimura T, Abe T, Nakamura T, Kitamura Y, Miwa T, Kameyama K, Hirose Y, Yoshida K.
ATRX represses alternative lengthening of telomeres
Source
Oncotarget
Napier CE, Huschtscha LI, Harvey A, Bower K, Noble JR, Hendrickson EA, Reddel RR.
CDKN2A Loss Is Associated with Shortened Overall Survival in Lower Grade (World Health Organization II-III) Astrocytomas
Source
J Neuropathol Exp Neurol
Reis GF, Pekmezci M, Hansen HM, Rice T, Marshall RE, Molinaro AM, Phillips JJ, Vogel H, Wiencke JK, Wrensch MR, Walsh KM, Perry A.
Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma
Source
J Pathol Clin Res
Slatter TL, Hsia H, Samaranayaka A, Sykes P, Clow W(, Devenish CJ, Sutton T, Royds JA, PC P, Cheung AN, Hung NA.
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas
Source
Nature Communications
Lauren Fishbein, Sanika Khare, Bradley Wubbenhorst, Daniel DeSloover, Kurt D’Andrea, Shana Merrill, Nam Woo Cho, Roger A. Greenberg, Tobias Else, Kathleen Montone, Virginia LiVolsi, Douglas Fraker, Robert Daber, Debbie L. Cohen, Katherine L. Nathanson.
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells
Source
Acta Neuropathol
Barszczyk M, Buczkowicz P, Castelo-Branco P, Mack SC, Ramaswamy V, Mangerel J, Agnihotri S, Remke M, Golbourn B, Pajovic S, Elizabeth C, Yu M, Luu B, Morrison A, Adamski J, Nethery-Brokx K, Li XN, Van Meter T, Dirks PB, Rutka JT, Taylor MD, Tabori U, Hawkins C.
Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas
Source
Oncotarget
Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N, Abedalthagafi M, Brown L, Wen PY, Reardon DA, Dunn IF, Folkerth RD, Santagata S, Lindeman NI, Ligon AH, Beroukhim R, Hornick JL, Alexander BM, Ligon KL, Ramkissoon SH.
Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH
Source
J Clin Oncol
Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, Huse JT, Mehta MP, Curran WJ Jr.
The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.
Source
Mod Pathol
Abedalthagafi M, Phillips JJ, Kim GE, Mueller S, Haas-Kogen DA, Marshall RE, Croul SE, Santi MR, Cheng J, Zhou S, Sullivan LM, Martinez-Lage M, Judkins AR, Perry A.
Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas.
Source
Brain Pathol
Nguyen DN, Heaphy CM, de Wilde RF, Orr BA, Odia Y, Eberhart CG, Meeker AK, Rodriguez FJ.
Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors
Source
Mod Pathol
de Wilde RF, Heaphy CM, Maitra A, Meeker AK, Edil BH, Wolfgang CL, Ellison TA, Schulick RD, Molenaar IQ, Valk GD, Vriens MR, Rinkes IH, Offerhaus GJ, Hruban RH, Matsukuma KE.
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Source
Oncotarget
Jiao Y, Killela PJ, Reitman ZJ, Rasheed BA, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi CJ, Lopez GY, He Y, Friedman HS, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon RE, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA Jr, Yan H.
Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway
Source
PLoS Genet
Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T, De S, Petrini JH, Sung PA, Jasin M, Rosenbluh J, Zwang Y, Weir BA, Hatton C, Ivanova E, Macconaill L, Hanna M, Hahn WC, Lue NF, Reddel RR, Jiao Y, Kinzler K, Vogelstein B, Papadopoulos N, Meeker AK, for the ALT Starr Cancer Consortium.
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
Source
Nature
Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel JO, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann MU, Scheurlen W, Pekrun A, Frühwald MC, Roggendorf W, Kramm C, Dürken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel P, Kulozik AE, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von Deimling A, Ichimura K, Collins VP, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister SM, Jabado N.
Altered telomeres in tumors with ATRX and DAXX mutations.
Source
Science
Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK.
Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas
Source
Clin Neuropathol
Haberler C, Wöhrer A.
追加しました。
抗原情報(Antigen Sequence)
Recombinant Protein Epitope Signature Tag (PrEST) antigen sequence: : AAWAEYEAEKKGLTMRFNIPTGTNLPPVSFNSQTPYIPFNLGALSAMSNQQLEDLINQGREKVVEATNSVTAVRIQPLEDIISAVWKENMNLSEAQVQALALSRQASQELDVKRREAIYNDVLTKQQMLISCVQRILMNRR[在庫・価格 :2025年04月27日 00時00分現在]
詳細 | 商品名 |
|
文献数 | ||
---|---|---|---|---|---|
PrEST Antigen ATRX, Human, Recombinant |
|
0 | |||
[在庫・価格 :2025年04月27日 00時00分現在]
PrEST Antigen ATRX, Human, Recombinant
文献数: 0
- 商品コード:APrEST74299
- メーカー:AAB
- 包装:100μl
- 価格:¥65,000
- 在庫:無(未発注)
- 納期:ご照会下さい ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等:
追加しました。
関連製品情報
高性能な免疫組織染色用の抗原賦活化装置: 「Decloaking Chamber NxGen」 ⇒ 詳細はこちら

追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。